BioTek Instruments Wins Prestigious Deane C. Davis Award!
June 1, 2010
BioTek Instruments, Inc., is the winner of the 2009 Deane C. Davis Outstanding Business of the Year Award. Named for former Vermont Governor Deane C. Davis, the award was presented to BioTek by current Vermont Governor Jim Douglas on Wednesday, May 26, 2010 at the Vermont Chamber Business & Industry Expo. The award, created by Vermont Business Magazine and the Vermont Chamber of Commerce, annually honors a Vermont company demonstrating a strong commitment to economic growth, a positive work environment and local community support.
In 2009, BioTek grew 13% over 2008 revenue, and made significant investments in electronic marketing, manufacturing expansion, and a new applications laboratory. Additionally, their workforce has grown 52% in the past five years. BioTek offers excellent benefits, personal development and a family atmosphere, and prides itself on an employee tenure that averages 10 or more years. Several charitable organizations and community projects are supported by the company, and employee involvement is encouraged. Additionally, BioTek's Green Team leads the company in safeguarding and continually improving Vermont’s precious environment through a variety of eco-friendly initiatives.
Briar Alpert, BioTek President & CEO, proudly accepted the award on behalf of the entire company and noted "The key to our success has been an engaged and passionate workforce. To have such a strong group of employees is a powerful competitive advantage, and it allows us, from right here in the State of Vermont, to compete with and beat best in class companies located anywhere in the world."
Click here to watch BioTek Instruments Win the Prestigious Deane C. Davis Award.
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.
For further information, contact:
Chere Griffin, Account Executive
Shaw & Todd Advertising and Marketing Communications